UNSPSC 51351612: Medroxyprogesterone acetate

This classification denotes a contraceptive and synthetic progestational hormone with the molecular formula C24H34O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2QI4IOI2G, chemically known as pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6.alpha.)- but generally known as medroxyprogesterone acetate, which bears US NIH Compound Identifier 4042. European Medicines Agency schedules Medroxyprogesterone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03114MIG.

UNSPSC 51351612 Medroxyprogesterone acetate is a Commodity code representing individual pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments under this code procure branded and generic medications—in this case, medroxyprogesterone acetate and other multi-source generic pharmaceuticals and over-the-counter products—through cooperative purchasing vehicles that aggregate demand across member jurisdictions and establish master agreements with manufacturers and authorized wholesalers. The solicitations target manufacturers and authorized distributors capable of supplying products with specific National Drug Codes, managing chargeback systems with wholesalers, and maintaining regulatory compliance including FDA approval, current Good Manufacturing Practices certification, and Drug Supply Chain Security Act compliance. Issuing bodies include state departments of administration, multistate cooperative purchasing alliances, and participating local government and healthcare facilities within those alliances.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and participate in Oregon and other member states. Evaluation criteria emphasize price competitiveness at 75 percent weight, with fixed pricing, compliance with administrative data format and EDI capability, and agreement to a 3 percent administrative fee together comprising the remaining 25 percent. Vendors must carry commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, with performance penalties ranging from $200 to $1,500 per violation. The contract term is two years for new responders with optional MMCAP extensions, or alignment with existing agreement expiration dates through June 30, 2028 for incumbent vendors.